AlphaMadera's AlphaVal page computes The Gorman-Rupp Company's fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag GRC as undervalued, fairly valued, or overvalued.

What is The Gorman-Rupp Company's fair value?

Fair value for GRC is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value GRC?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from GRC's most recent reported fundamentals.

GRC - The Gorman-Rupp Company

Price: -- -- | CONSENSUS: Hold DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Stable Earnings Power 65% confidence

Primary model: P/Adj-EPS × Normalized Multiple

Valuation Signal Overvalued Moderate

Trading 39.5% above fair value

Current Price $72.66

Bear Case $41.67 42.6% downside ($41.67 - $72.66) / $72.66 = -42.6% $2.64 × 16x P/E

Fair Value $52.09 28.3% downside ($52.09 - $72.66) / $72.66 = -28.3% $2.64 × 20x P/E

Bull Case $62.51 14.0% downside ($62.51 - $72.66) / $72.66 = -14.0% $2.64 × 24x P/E

Adjust Assumptions

P/E Multiple

19.8x

Adjusted EPS

2.64$

Key Value Driver

Normalized P/E multiple (20x base case)

Implied Market Multiple 27.6x

Plain-Language Summary

Applying a 20x P/E to adjusted EPS of $2.64, the base-case value is $52.09 per share. DDM cross-check: $14.26.

Warnings

⚠ The company's reported profits differ from official accounting profits by 30%. Check what costs are being left out of the adjusted number.

ℹ Dividend-based valuation: $14.26 (below our primary estimate by 73%). Large gaps may signal the dividend doesn't reflect full earning power.

Key Risks

Growth DCF inappropriate — terminal value assumptions dominate
EV/EBITDA misleading for regulated businesses where capex is mandated
Regulatory risk is a fat tail not visible in normal multiples